

Endoscopic assessment and S1P receptor modulation targeting mucosal healing in ulcerative colitis

Date 2025. **9.5** Fri 13:50-14:30

Venue Room B Toshi Center Hotel Tokyo 3F Cosmos Hall 2
2-4-1 Hirakawa-cho, Chiyoda-ku, Tokyo 102-0093, Japan

Moderator

Masayuki Saruta, MD, PhD

Division of Gastroenterology and Hepatology, Department of Internal Medicine,
The Jikei University School of Medicine

Speaker

Mikihiro Fujiya, MD, PhD

Division of Gastroenterology, Department of Internal Medicine,
Asahikawa Medical University

Co-sponsored: The 1st JGES International / Pfizer Japan Inc.



Etrasimod is an oral, once daily, selective sphingosine 1-phosphate 1,4,5 (S1P) receptor modulator for the treatment of moderately to severely active ulcerative colitis*

*INDICATIONS in Japan: Treatment of moderate to severe ulcerative colitis (only in patients who have had an inadequate response to existing therapies)